SOURCE: Novacea

February 08, 2007 17:20 ET

Novacea to Present at BIO CEO Conference

SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- February 8, 2007 -- Novacea, Inc. (NASDAQ: NOVC) today announced that John Curd, M.D., the company's president and chief medical officer, will be presenting at the Biotechnology Industry Organization (BIO) CEO conference's prostate cancer panel in New York City on February 14, 2007 at 9:00 am Eastern Time (ET). Entitled "Prostate Cancer - Shrinking a Problem in a Growing Aging Population," the panel discussion will be webcast from the Duke of Windsor Room, Waldorf-Astoria Hotel.

An audio webcast of the presentation will be available to all interested parties through the Novacea website, www.novacea.com. A replay will be available at www.novacea.com starting approximately 24 hours after completion of the live webcast, and will remain available for 21 days thereafter.

About Novacea

Novacea, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing novel cancer therapies. Novacea has two product candidates in clinical trials, including Asentar™, which currently is in a Phase 3 clinical trial for androgen-independent prostate cancer, or AIPC. Novacea's second product candidate, AQ4N, is a hypoxia-activated prodrug and is being investigated in combination with radiation and chemotherapy in a Phase 1/2 clinical trial in brain tumors such as glioblastoma multiforme.

Note: Except for the historical information contained herein, the matters set forth in this press release, including statements as to financial guidance, development, clinical studies, regulatory review and approval, and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: early stage of development; the focus, conduct, enrollment and timing of our clinical trials; regulatory review and approval of product candidates; commercialization of products; developments relating to our licensing and collaboration agreements; market acceptance of products; funding requirements; intellectual property protection for our product candidates; competing products and other risks detailed from time to time under the heading "Risk Factors" in our most recent Quarterly Report on Form 10-Q, as may be updated from time to time by our future filings under the Securities Exchange Act. If one or more of these risks or uncertainties materialize, or if any underlying assumptions prove incorrect, our actual performance or results may vary materially from any future performance or results expressed or implied by these forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

Contact Information